Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer

Urology

Volumn 51, Issue 5 SUPPL. A, 1998, Pages 89-97

  Murphy, Gerald P ^a,g   Kenny, Gerald M ^a   Ragde, Haakon ^a   Wolfert, Robert L ^b   Boynton, Alton L ^a   Holmes, Eric H ^a   Misrock, S Leslie ^c   Bartsch, Georg ^d   Klocker, Helmut ^d   Pointner, Joseph ^d   Reissigl, A ^d   McLeod, David G ^e   Douglas, Thomas ^e   Morgan, Ted ^e   Gilbaugh Jr , James ^f  

^a NORTHWEST HOSPITAL   (United States)

^b Hybritech Incorporated   (United States)

^c Pennie and Edmonds   (United States)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e WALTER REED ARMY MEDICAL CENTER   (United States)

^f Private Practice   (United States)

^g PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3F5.4G6; MONOCLONAL ANTIBODY 7E11.C5; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER SCREENING; CANCER STAGING; CARBOXY TERMINAL SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROSTATITIS;

ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTIGENS, SURFACE; BLOTTING, WESTERN; CARBOXYPEPTIDASES; EPITOPES; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; HYBRIDOMAS; MALE; PROGNOSIS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROSTATITIS; RADIOIMMUNOASSAY; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 0031834798     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00082-X     Document Type: Article

References (16)

1. Murphy G.P., Holmes E.H., Boynton A.L., Kenny G.M., Ostenson R.C., Erickson S.J., Barren R.J. A comparison of prostate specific antigen, prostate specific membrane antigen and LNCaP based ELISA assays in prostatic cancer patients and patients with benign prostatic enlargement. Prostate. 26:1995;164-168.
2. Murphy G.P., Ragde H., Kenny G., Barren R. III, Erickson S., Tjoa B., Boynton A., Holmes E., Gilbaugh J., Douglas T. Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients. Anticancer Res. 15:1995;1473-1480.
3. Douglas T.H., Connelly R.R., McLeod D.G., Erickson S.J., Barren R.J., Murphy G.P. The effects of exogenous testosterone replacement on prostate specific antigen and prostate specific membrane antigen levels in hypogonadal men. J Surg Oncol. 59:1995;246-250.
4. Rochon Y.P., Horoszewicz J.S., Boynton A.L., Holmes E.H., Barren R.J., Erickson S.J., Kenny G.M., Murphy G.P. Western blot assay for prostate specific membrane antigen in serum of prostate cancer patients. Prostate. 25:1994;219-223.
5. Galfré G., Milstein C. Immunochemical Techniques, Part B. Langove J.J., VanVunakis H. Methods in Enzymology. 1981;3-47 Academic Press, San Diego.
6. Pelletier D.B., Boynton A. Dissociation of PDGF receptor tyrosine kinase activity from PDGF-mediated inhibition of gap junctional communication. J Cell Physiol. 158:1994;427-434.
7. Horoszewicz J.S., Kawinski E., Murphy G.P. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res. 7:1987;927-936.
8. Tillyer C.R., Konings M., Gobin P.T., Iqbal J. Disagreement between the Roche Cobas Core and Hybritech Tandem-E PSA assays when measuring free, complexed and total serum prostate specific antigen. Ann Clin Biochem. 31:1994;501-505.
9. DeLeo J. Receiver operating characteristic laboratory (ROCLAB): software for developing decision strategies that account for uncertainty. Second International Symposium on Uncertainty Modeling Analysis. 1993;318-325 IEEE Computer Society Press, New York.
10. Metz C.E. Basic Principles of ROC Analysis. Semin Nucl Med. 4:1978;283-298.
11. Pfaffenberger R.C., Paterson J.H. Statistical Methods for Business and Economics. 1977;Richard Irwin, Inc, Chicago, Illinois.
12. Israeli R.S., Powell C.T., Corr J.G., Fair W.R., Heston W.D. Expression of the prostate-specific membrane antigen. Cancer Res. 54:(7):1994;1807-1811.
13. Troyer J.K., Feng Q., Beckett M.L., Wright G.L. Biochemical characterization and mapping of the 7E11-C5 3 epitope of the prostate-specific membrane antigen . Urol Oncol. 1:1995;29-37.
14. Troyer J.K., Beckett M.L., Wright G.L. Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer. 62:1995;552-558.
15. Su S.L., Huang I.P., Fair W.R., Powell C.T., Heston W.D. Alternatively spliced variants of prostate-specific membrane antigen RNA; ratio of expression as a potential measurement of progression. Cancer Res. 55:(7):1995;1441-1443.
16. Carter R.E., Feldman A.R., Coyle J.T. Prostate-specific membrane antigen is a hydrolase with substrate and pharmacologic characteristics of a neuropeptidase. Proc Nat Acad Sci USA. 39:1996;749-753.